呕吐的实际成本——昂丹司琼与甲氧氯普胺控制癌症化疗患者呕吐的经济学分析

The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer.

作者信息

Cunningham D, Gore M, Davidson N, Miocevich M, Manchanda M, Wells N

机构信息

Royal Marsden Hospital, Sutton, Surrey, UK.

出版信息

Eur J Cancer. 1993;29A(3):303-6. doi: 10.1016/0959-8049(93)90372-m.

DOI:10.1016/0959-8049(93)90372-m

PMID:8398322

Abstract

The cost effectiveness of ondansetron was compared with that of metoclopramide in the prevention of acute emesis due to highly emetogenic chemotherapy in an open, randomised, parallel group pilot study. Ondansetron was given as three 8 mg intravenous doses (0, 4 and 8 h) and metoclopramide as an intravenous loading dose (3 mg/kg) followed by a maintenance dose of 0.5 mg/kg/h for 8 h. Therapeutic outcomes and full utilisation costs, that is nursing time, material costs, in addition to drug acquisition prices were recorded for each antiemetic for 24 h following chemotherapy. The cost per successfully treated patient (< or = 1 emetic episode and no adverse events) was 95.20 pounds for ondansetron and 92.18 pounds for metoclopramide. The results of the study therefore suggest that for the control of acute emesis due to highly emetogenic chemotherapy ondansetron and metoclopramide are equally cost-effective treatments.

摘要

在一项开放性、随机、平行组的试点研究中，比较了昂丹司琼与甲氧氯普胺预防高致吐性化疗所致急性呕吐的成本效益。昂丹司琼静脉注射3次，每次8mg（分别在0、4和8小时），甲氧氯普胺静脉注射负荷剂量（3mg/kg），随后以0.5mg/kg/h的维持剂量持续8小时。记录化疗后24小时内每种止吐药的治疗结果和全部使用成本，即护理时间、材料成本以及药品采购价格。对于成功治疗的患者（呕吐发作≤1次且无不良事件），昂丹司琼的成本为95.20英镑，甲氧氯普胺为92.18英镑。因此，该研究结果表明，对于控制高致吐性化疗所致的急性呕吐，昂丹司琼和甲氧氯普胺是成本效益相当的治疗方法。